LIVE
KVUE
Kenvue Inc. · Consumer Staples
$18.81
+3.67% this month
VERSUS
⟷
COMPARE
PG
The Procter & Gamble Company · Consumer Staples
$148.37
-0.83% this month
Scoreboard verdict
Across AI score, momentum, valuation, upside, operating margin
KVUE
1
PG
3
Comparison scoreboard
PG LEADS 3/5AI Score
KVUE 23.7
PG ✓41.1
1Y Return
KVUE -9.81%
PG ✓-5.53%
Fwd P/E
KVUE ✓15.15
PG 20.82
Target Up.
KVUE +4.14%
PG ✓+11.15%
Op. Margin
KVUE N/A
PG 23.05%
Metrics last refreshed: 7/14/2026
Quick take
KVUE vs PG: Kenvue vs Procter & Gamble Stock Comparison: AI Score, Valuation, Performance and Upside
Kenvue is a focused consumer health company with iconic self-care brands that was spun off from J&J in 2023, while P&G is the world's largest consumer staples company with 67+ years of consecutive dividend growth. P&G is the higher-quality, more diversified consumer staples compounder; Kenvue is the pure-play consumer health brand portfolio at a lower valuation with more focused management.
KVUE vs PG is a newly independent consumer health brand portfolio versus the world's most trusted consumer staples compounder — Kenvue wins if independence unlocks brand investment and margin improvement; P&G wins if pricing power, global scale, and dividend growth compound consistently.
Live analysis · updated 7/14/2026
PG holds the edge across 3 of 5 key metrics in this comparison. PG has delivered stronger 1-year price return (-5.53% vs -9.81%), though KVUE has the better forward P/E setup (15.15x vs 20.82x for PG). Analyst consensus implies meaningfully more upside for PG (+11.15%) than for KVUE (+4.14%).
Normalized 1Y performance
KVUE
PG
Recent returns
KVUE
PG
Analyst price targets & sentiment
KVUE · 12 analysts
STRONG BUYHOLDSTRONG SELL
Hold (2.8/5.0)
Price target range
analyst low$18.00
analyst high$23.00
analyst mean$19.58
current price$18.81
+4.1% upside to analyst mean
PG · 23 analysts
STRONG BUYHOLDSTRONG SELL
Buy (2.0/5.0)
Price target range
analyst low$140.00
analyst high$190.00
analyst mean$163.43
current price$148.37
+11.1% upside to analyst mean
Who should consider this stock?
KVUE may suit investors who:
- →want focused consumer health brand exposure through Tylenol, Listerine, Neutrogena, and Band-Aid
- →believe independence from J&J allows Kenvue to invest more efficiently in its specific brand portfolio
- →value Kenvue's lower valuation vs P&G for similar consumer brand quality in the health category
- →prefer a pure-play consumer health company over P&G's broader staples diversification
PG may suit investors who:
- →want the world's most trusted consumer staples compounder with 67+ years of dividend growth
- →value P&G's global scale, pricing power, and category leadership across essential household products
- →prefer Dividend Aristocrat exposure with the longest track record in consumer goods
- →are comfortable paying a premium multiple for P&G's durable brand quality and global distribution
Performance & AI score
| Metric | KVUE | PG |
|---|---|---|
| AI score | 23.7 | 41.1 |
| AI rank | #3460 | #1064 |
| Latest close | $18.81 | $148.37 |
| 1M return | +3.67% | -0.83% |
| 6M return | +13.24% | +4.58% |
| 1Y return | -9.81% | -5.53% |
$10,000 invested — hypothetical growth (dividends reinvested)
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | KVUE | PG |
|---|---|---|
| 1Y ago | $9.44K (-5.6%) started 2025-07-14 | $9.65K (-3.5%) started 2025-07-14 |
| 5Y ago | $8.98K (-10.2%) started 2023-05-04 | $13.17K (+31.7%) started 2021-07-14 |
| 10Y ago | $8.98K (-10.2%) started 2023-05-04 | $29.1K (+191.0%) started 2016-07-14 |
Hypothetical — past performance does not guarantee future results.
Valuation & upside potential
| Metric | KVUE | PG |
|---|---|---|
| Market cap | $36.11B | $342.4B |
| Trailing P/E | 22.39 | 21.50 |
| Forward P/E | 15.15 | 20.82 |
| Price/Sales | 2.36 | 4.58 |
| EV/Revenue | 2.92 | 4.25 |
| Analyst target | $19.58 | $163.43 |
| Target upside | +4.14% | +11.15% |
Growth, profitability & risk
| Metric | KVUE | PG |
|---|---|---|
| Revenue growth | 4.50% | 7.40% |
| Earnings growth | 46.90% | 5.80% |
| EPS growth | +46.90% | +5.80% |
| FCF margin | +12.15% | +14.68% |
| Operating margin | N/A | 23.05% |
| Profit margin | 10.61% | 19.16% |
| ROIC proxy | 15.70% | 31.11% |
| Return on equity | 15.70% | 31.11% |
| Dividend yield | 4.26% | 2.90% |
| Beta | 0.44 | 0.38 |
| Debt/equity | 82.97 | 67.65 |
| Current ratio | 0.98 | 0.73 |
| Quick ratio | 0.61 | 0.49 |
Drawdown & downside risk
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
1Y risk snapshot
KVUE max drawdown37.63%
PG max drawdown16.15%
KVUE max wkly drop16.21%
PG max wkly drop8.12%
5Y risk snapshot
KVUE max drawdown44.08%
PG max drawdown23.77%
KVUE max wkly drop16.21%
PG max wkly drop8.92%
10Y risk snapshot
KVUE max drawdown44.08%
PG max drawdown23.77%
KVUE max wkly drop16.21%
PG max wkly drop16.27%
Performance metrics by period
| Period | Metric | KVUE | PG |
|---|---|---|---|
| 1Y | Growth | -9.81% | -3.51% |
| CAGR | -9.82% | -3.52% | |
| Sharpe ratio | -0.29 | -0.32 | |
| Max drawdown | 37.63% | 16.15% | |
| Max daily drop | 13.22% | 3.56% | |
| Max wkly drop | 16.21% | 8.12% | |
| 5Y | Growth | -21.02% | +18.71% |
| CAGR | -7.12% | +3.49% | |
| Sharpe ratio | -0.28 | 0.03 | |
| Max drawdown | 44.08% | 23.77% | |
| Max daily drop | 13.22% | 6.23% | |
| Max wkly drop | 16.21% | 8.92% | |
| 10Y | Growth | -21.02% | +120.62% |
| CAGR | -7.12% | +8.24% | |
| Sharpe ratio | -0.28 | 0.28 | |
| Max drawdown | 44.08% | 23.77% | |
| Max daily drop | 13.22% | 8.74% | |
| Max wkly drop | 16.21% | 16.27% |
Business comparison
| Category | KVUE | PG |
|---|---|---|
| Company | Kenvue Inc. | The Procter & Gamble Company |
| Sector | Consumer Staples | Consumer Defensive |
| Industry | N/A | Household & Personal Products |
| Core business | Consumer health company spun off from Johnson & Johnson in 2023 with iconic self-care brands including Tylenol, Neutrogena, Listerine, Band-Aid, Aveeno, and Nicorette. Kenvue operates across three segments: skin health & beauty, essential health, and self care. | World's largest consumer staples company with Tide, Pampers, Gillette, Head & Shoulders, Oral-B, Always, Bounty, Febreze, and Charmin among its brand portfolio. P&G serves consumers in 180+ countries. |
| Investor focus | Organic revenue growth across skin health and essential health segments, Neutrogena brand recovery, margin improvement, and dividend sustainability post-separation. | Organic revenue growth from pricing and volume, market share across core categories, emerging market penetration, and dividend growth (67+ consecutive years of dividend increases). |
KVUE strengths
- →Portfolio of #1 or #2 market-share brands in self-care categories creates durable consumer demand
- →Tylenol, Listerine, and Band-Aid are generational brands with extremely high consumer trust and repurchase rates
- →Independent company structure allows Kenvue to focus capital and management attention entirely on consumer health
PG strengths
- →P&G's portfolio of #1 brands across essential categories (laundry, diapers, shaving, feminine care) represents the most trusted consumer staples franchise globally
- →Pricing power through premium brand investment allows P&G to pass through commodity cost inflation while protecting margins
- →67+ years of consecutive dividend increases make P&G one of the most reliable dividend growth stocks in the world
Risks to watch — KVUE
- →Some Kenvue brands face generic and private-label competition in drugstores and mass retail channels
- →Neutrogena has faced brand challenges and increased competition in the skin care category
- →Kenvue carries post-separation debt that limits capital allocation flexibility vs a debt-free consumer staples company
Risks to watch — PG
- →Private-label share gains in inflationary environments put volume pressure on branded consumer staples
- →P&G trades at a premium multiple that embeds a high-quality assumption — any organic growth slowdown can cause multiple compression
- →Emerging market FX headwinds from local currency depreciation affect USD-reported results despite strong local volume growth
Frequently asked questions
Free public comparison
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Related comparisons
More comparisons
Browse all 1,000 comparisons →